Longboard Pharmaceuticals (Nasdaq:LBPH) - Prezzo delle azioni, notizie e analisi

LBPH Panoramica delle azioni

Longboard Pharmaceuticals, Inc. è una società biofarmaceutica in fase clinica che si concentra sullo sviluppo di farmaci innovativi e trasformativi per le malattie neurologiche. Maggiori dettagli

LBPH analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Si prevede che gli utili diminuiranno in media di 7.6% all'anno per i prossimi 3 anni

+ 1 più rischio

Longboard Pharmaceuticals, Inc. Concorrenti

Ligand Pharmaceuticals

NasdaqGM:LGND

US$2.3b

Wave Life Sciences

NasdaqGM:WVE

US$2.2b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$2.1b

Belite Bio

NasdaqCM:BLTE

US$2.3b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Longboard Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$59.91
Massimo di 52 settimane	US$59.95
Minimo di 52 settimane	US$3.60
Beta	1.09
1Variazione di 1 mese	0.52%
Variazione a 3 mesi	70.20%
Variazione di 1 anno	1,405.28%
3Variazione a 3 anni	954.75%
Variazione a 5 anni	n/a
Variazione dall'IPO	259.82%

Notizie e aggiornamenti recenti

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Oct 15

My Strategy For Longboard Pharmaceuticals After Its Big Run

Aug 28

Recent updates

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Oct 15

My Strategy For Longboard Pharmaceuticals After Its Big Run

Aug 28

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Jul 12

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Mar 16

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Oct 03

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Dec 25

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

Sep 10

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

May 28

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Feb 11

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Oct 27

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Jun 12

Longboard Pharmaceuticals EPS beats by $0.29

May 10

Rendimenti per gli azionisti

	LBPH	US Pharmaceuticals	US Mercato
7D	0.3%	2.8%	2.2%
1Y	1,405.3%	11.8%	32.6%

Ritorno vs Industria: LBPH ha superato il US Pharmaceuticals che ha restituito 11.8 % nell'ultimo anno.

Rendimento vs Mercato: LBPH ha superato il mercato US che ha restituito 32.6 % nell'ultimo anno.

Volatilità dei prezzi

Is LBPH's price volatile compared to industry and market?
LBPH volatility
LBPH Average Weekly Movement	16.9%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di LBPH è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di LBPH è diminuita da 46% a 17% nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2020	50	Kevin Lind	www.longboardpharma.com

Longboard Pharmaceuticals, Inc. è una società biofarmaceutica in fase clinica che si concentra sullo sviluppo di farmaci innovativi e trasformativi per le malattie neurologiche. L'azienda sviluppa la bexicaserina (LP352), che ha completato la sperimentazione clinica di Fase 1b/2a per il trattamento delle crisi associate alle encefalopatie epilettiche e dello sviluppo. Sviluppa inoltre LP659, un modulatore del recettore S1P per il trattamento di malattie neurologiche.

Longboard Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Longboard Pharmaceuticals con la sua capitalizzazione di mercato?
LBPH statistiche fondamentali
Capitalizzazione di mercato	US$2.33b
Guadagni(TTM)	-US$76.34m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-30.6x

Rapporto P/E

LBPH è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
LBPH Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$76.34m
Guadagni	-US$76.34m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.96
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato LBPH nel lungo periodo?

Vedi performance storica e confronto

LBPH Panoramica delle azioni

Analisi del rischio

Longboard Pharmaceuticals, Inc. Concorrenti

NasdaqGM:LGND

US$2.3b

NasdaqGM:WVE

US$2.2b

NasdaqGS:AMPH

US$2.1b

NasdaqCM:BLTE

US$2.3b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Langkawi Corporation entered into an Agreement and Plan of Merger to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.4 billion.

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

My Strategy For Longboard Pharmaceuticals After Its Big Run

Recent updates

Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Langkawi Corporation entered into an Agreement and Plan of Merger to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.4 billion.

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

My Strategy For Longboard Pharmaceuticals After Its Big Run

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) dropped from Russell Small Cap Comp Value Index

Longboard Pharmaceuticals, Inc. Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

Longboard Pharmaceuticals, Inc. Announces Positive Interim Results from Its Ongoing 52-Week Open-Label Extension of the Pacific Study Evaluating Bexicaserin (Lp352)

Price target decreased by 7.2% to US$41.75

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Insufficient new directors

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

New major risk - Revenue and earnings growth

Longboard Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $210 million.

Price target increased by 43% to US$28.67

Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (Dees)

Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers

New minor risk - Market cap size

New minor risk - Share price stability

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Longboard Pharmaceuticals, Inc. Completes Enrollment of Phase 1b/2a Pacific Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

New major risk - Financial position

Price target decreased by 14% to US$17.00

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

High number of new and inexperienced directors

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Longboard Pharmaceuticals Announces Positive Topline Data from A Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

Price target decreased to US$19.74

Price target decreased to US$22.80

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 24, 2022

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Longboard Pharmaceuticals Provides Corporate Update

Longboard Pharmaceuticals EPS beats by $0.29

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Longboard Pharmaceuticals, Inc. Riepilogo dei fondamenti

0.0x

-30.6x

Guadagni e ricavi